This content was created by Everyday Health Media on behalf of an advertiser.
More Information.
Content on this page was created by the Everyday Health Media team and is funded by an advertiser. The content conforms to Everyday Health Media’s editorial standards for accuracy, objectivity, and balance. The advertiser may select the specialty area but does not edit or approve the content.
Update: B-Cell and Follicular Lymphoma
Pediatric Follicular Lymphoma: How Does it Differ from FL in Adults?
Follicular lymphoma is much less common in children than adults, but it does present in unique ways that community oncologists could benefit from recognizing, says Brian Hill, MD, PhD, of Cleveland Clinic. (1:41)
Non-Hodgkin Lymphoma Subtypes and Prediagnostic Circulating Immune Markers
This study is reportedly the first to investigate associations between circulating immune markers and risk of non-Hodgkin lymphoma (NHL), across both common and rarer NHL subtypes and across different periods of follow-up.
In Women with DLBCL, Chronotherapy Improves Outcomes
This retrospective study demonstrated improved outcomes (progression-free survival and overall survival) in female patients with diffuse large B-cell lymphoma who received chemotherapy in the afternoon rather than in the morning.
.jpg)
Q&A: Possible Precursors to Follicular Lymphoma
Joe Schroers-Martin, MD, and Ash A. Alizadeh, MD, PhD, from Stanford University, discuss recent research into pre-diagnostic mutations that may help predict future disease.
Q&A: Shyam A. Patel, MD, PhD, on DLBCL — Where We Are and Where We’re Headed
In this interview, Dr. Patel discusses the curative potential of novel therapeutic agents, issues with tolerability, and improvements he expects in the next few years.
Q&A: Jeff R. Gehlhausen, MD, PhD, on Random Skin Biopsies in the Diagnosis of Intravascular Large B-cell Lymphoma
In an interview with MedPage Today, Dr. Gehlhausen, of the Yale School of Medicine, discussed the use of this diagnostic tool, describing the techniques that are available and important considerations.
Q&A: Thomas S.C. Ng, MD, PhD, and Antonio R. Lopez on Neurolymphomatosis in Diffuse Large B-cell Lymphoma
Dr. Ng and Mr. Lopez discuss the diagnosis of this rare lymphoma manifestation in an interview with MedPage Today.
Q&A: Sendhilnathan Ramalingam, MD, on Follicular Lymphoma Prognosis
Dr. Ramalingam discusses the utility of prognostic indicators such as tumor grade, mutational status, and more in follicular lymphoma.
.jpg)
In Follicular Lymphoma, What are the Risk Factors for Histological Transformation?
Utilizing data from the GALLIUM trial, investigators identified several risk factors for histological transformation of follicular lymphoma in a recent secondary analysis.
Low/Intermediate FLIPI and Not Transformed Follicular Lymphoma Has a Favorable Outcome
This retrospective analysis of patients with follicular lymphoma found that a Follicular Lymphoma International Prognostic Index low/intermediate score in the absence of histological transformation was associated with a good prognosis even for patients with early relapse.
Progression Within 24 Months Predicts Poorer Survival Following Relapse or Progression in Follicular Lymphoma
Patients with FL who experience disease progression within 24 months of first-line therapy have poorer overall survival compared with those who do not have progression within 24 months.